Grant: Engage Grants Program
McMaster University
$25,000.00
Activity-based protein profiling to confirm the indel-binding properties of small molecule inhibitors to novel Staphylococcus aureus and Leishmania donovani drug targets
FY 2013-14
Summary
Infectious diseases remain among the top causes of morbidity and mortality across the globe. Despite thispressing clinical need there has been little innovation in drug/target interactions. The dominant paradigm forsuccessful anti-infective drugs has been the targeting of pathogen-specific proteins or physiology essential forcell viability. This represents a very narrow spectrum of essential biochemistry that is proving increasinglychallenging to target. Indel Therapeutics is innovating in this area by focusing not on entire protein targetsunique to pathogens, but on selected regions of essential proteins where insertions and deletions (indels) areunique to pathogens. This greatly expands the target space available for anti-infective drug discovery.Using a propriety bioinformatics platform, Indel Therapeutics has identified indels in Leishmania elongationfactor-1 alpha (EF-1a) and pyruvate kinase (PK) from Staphylococcus aureus thereby covering both importantparasite and bacterial pathogens. Using a virtual screening approach that targets the indel site followed byenzyme inhibition and microbiological assays, small molecule inhibitors of both EF-1a and PK have beenidentified and prioritized. What Indel Therapeutics currently lacks is definitive evidence that these compoundsare targeting the indel region of the proteins and whether biological activity correlates with targeting of eitherEF-1a or PK in the cell. The technology most appropriate to answer these questions is Affinity Based ProteinProfiling (ABPP). In ABPP, derivatives of hit molecules are prepared with two traits: first is the ability tocovalently modify interacting proteins (e.g. through a photoaffinity label) and second is a chemical 'handle' toidentify the molecule and retrieve the interacting protein from the cell for analysis by mass spectrometry. TheWright lab has extensive experience with ABPP and has direct access to all of the necessary infrastructurerequired for this technology. The proposed new project will merge the interests of the industrial partner withthe expertise in the Wright lab to advance the project to the next stage.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
448143-2013
Name nom
Wright, Gerard
Department département
Biochemistry and Biomedical Sciences
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Activity-based protein profiling to confirm the indel-binding properties of small molecule inhibitors to novel Staphylococcus aureus and Leishmania donovani drug targets
Keyword
NSERC
Application summary
Infectious diseases remain among the top causes of morbidity and mortality across the globe. Despite thispressing clinical need there has been little innovation in drug/target interactions. The dominant paradigm forsuccessful anti-infective drugs has been the targeting of pathogen-specific proteins or physiology essential forcell viability. This represents a very narrow spectrum of essential biochemistry that is proving increasinglychallenging to target. Indel Therapeutics is innovating in this area by focusing not on entire protein targetsunique to pathogens, but on selected regions of essential proteins where insertions and deletions (indels) areunique to pathogens. This greatly expands the target space available for anti-infective drug discovery.Using a propriety bioinformatics platform, Indel Therapeutics has identified indels in Leishmania elongationfactor-1 alpha (EF-1a) and pyruvate kinase (PK) from Staphylococcus aureus thereby covering both importantparasite and bacterial pathogens. Using a virtual screening approach that targets the indel site followed byenzyme inhibition and microbiological assays, small molecule inhibitors of both EF-1a and PK have beenidentified and prioritized. What Indel Therapeutics currently lacks is definitive evidence that these compoundsare targeting the indel region of the proteins and whether biological activity correlates with targeting of eitherEF-1a or PK in the cell. The technology most appropriate to answer these questions is Affinity Based ProteinProfiling (ABPP). In ABPP, derivatives of hit molecules are prepared with two traits: first is the ability tocovalently modify interacting proteins (e.g. through a photoaffinity label) and second is a chemical 'handle' toidentify the molecule and retrieve the interacting protein from the cell for analysis by mass spectrometry. TheWright lab has extensive experience with ABPP and has direct access to all of the necessary infrastructurerequired for this technology. The proposed new project will merge the interests of the industrial partner withthe expertise in the Wright lab to advance the project to the next stage.